Latest News on ATYR

Financial News Based On Company


Advertisement
Advertisement

aTyr presents preclinical data on osteosarcoma treatment candidate

https://www.investing.com/news/company-news/atyr-presents-preclinical-data-on-osteosarcoma-treatment-candidate-93CH-5038608
aTyr Pharma Inc. presented preclinical data for ATYR2810, a monoclonal antibody designed to treat osteosarcoma, at the Connective Tissue Oncology Society 2026 Annual Meeting. Studies showed ATYR2810 inhibited tumor growth and metastasis to the lungs in mouse models without overt toxicity. This treatment targets neuropilin-2 (NRP2), a receptor linked to cancer progression and metastasis, offering a potential new approach for this aggressive bone cancer.

aTyr Pharma Presents Preclinical Data for NRP2-Targeting Antibody ATYR2810 at the Connective Tissue Oncology Society (CTOS) 2026 Annual Meeting

https://sg.finance.yahoo.com/news/atyr-pharma-presents-preclinical-data-120000037.html
aTyr Pharma announced preclinical data for its NRP2-targeting antibody, ATYR2810, at the Connective Tissue Oncology Society (CTOS) 2026 Annual Meeting. The data shows ATYR2810 significantly inhibits tumor growth and metastasis of osteosarcoma to the lungs in preclinical models, with sustained anti-tumor effects even after treatment cessation and no overt toxicity. This research highlights ATYR2810's potential as a promising therapeutic candidate for aggressive cancers, particularly osteosarcoma, by targeting NRP2 to reprogram tumor-associated macrophages and reduce metastases.

Form 8K aTyr Pharma Inc For: 13 November By Investing.com

https://ca.investing.com/news/stock-market-news/form-8k-atyr-pharma-inc-for-13-november-93CH-4957778
This article from Investing.com announces the filing of a Form 8K by aTyr Pharma Inc on November 13. The brief notice highlights the immediate availability of this financial disclosure. The article provides no further details about the content of the Form 8K.

aTyr Pharma regains compliance with Nasdaq minimum bid price rule By Investing.com

https://in.investing.com/news/stock-market-news/atyr-pharma-regains-compliance-with-nasdaq-minimum-bid-price-rule-93CH-5703967
aTyr Pharma announced it has regained compliance with the Nasdaq minimum bid price requirement, with its common stock trading above $1.00 for ten consecutive business days. This follows previous notices from Nasdaq regarding non-compliance. Despite this, InvestingPro analysis suggests the stock remains undervalued, having declined significantly over the past year.

aTyr Pharma Regains Nasdaq Minimum Bid Price Compliance

https://www.tradingview.com/news/tradingview:cf6094bc3ee51:0-atyr-pharma-regains-nasdaq-minimum-bid-price-compliance/
aTyr Pharma (ATYR) has regained compliance with Nasdaq's $1.00 minimum bid price requirement. The company's stock maintained a closing bid price of at least $1.00 for ten consecutive business days, from October 30 to November 12, 2026. As a result, aTyr Pharma no longer has any outstanding deficiency notices from Nasdaq.
Advertisement

aTyr Pharma regains compliance with Nasdaq minimum bid price rule

https://www.investing.com/news/sec-filings/atyr-pharma-regains-compliance-with-nasdaq-minimum-bid-price-rule-93CH-5026487
aTyr Pharma (NASDAQ:ATYR) has announced it has regained compliance with Nasdaq's minimum bid price requirement, with its common stock trading above $1.00 for ten consecutive business days. This follows previous notices from Nasdaq regarding non-compliance and an extension granted until November 30, 2026. Despite this positive development, InvestingPro analysis indicates the stock remains undervalued, having declined 78% over the past year.

ATYR slides over 6% as price targets are cut and technical weakness persists

https://tradersunion.com/news/stocks/show/4203661-atyr-pharma-slides-6-22percent-today/
aTyr Pharma Inc (ATYR) experienced a 6.22% decline in its stock price due to analyst reports lowering earnings expectations and price targets. The stock also exhibits technical weakness, trading below its 50-day and 200-day moving averages. Experts highlight negative sentiment from analyst downgrades and increased loss projections, with immediate support at $6.7 being a critical level for the stock's future direction.

aTyr CEO's December talk will be webcast; its replay will be available for at least 90 days.

https://www.stocktitan.net/news/ATYR/a-tyr-pharma-to-participate-in-upcoming-investor-thww8b1j9a7y.html
aTyr Pharma (Nasdaq: ATYR) announced its participation in two investor conferences in November and December 2026. President and CEO Sanjay S. Shukla will conduct one-on-one meetings and a fireside chat, which will be webcast and available for replay for 90 days. The company's stock, ATYR, saw a 9.66% decline against its previous close on the day this news was released.

ATYR Maintained by Wells Fargo -- Price Target Raised to $4.00

https://www.gurufocus.com/news/9181335/atyr-maintained-by-wells-fargo-price-target-raised-to-400
Wells Fargo has maintained its "Equal-Weight" rating on aTyr Pharma (ATYR) but significantly increased its price target from $1.00 to $4.00, reflecting growing confidence in the biotechnology company's growth potential. While GuruFocus's GF Value™ indicates ATYR is undervalued by 81.9%, its low GF Score™ of 34/100, astronomical Price-to-Sales ratio, and negative EPS suggest considerable risks, including the possibility of a value trap for investors.

aTyr Pharma files prospectus to sell up to $79.99 million in common stock

https://uk.investing.com/news/stock-market-news/atyr-pharma-files-prospectus-to-sell-up-to-7999-million-in-common-stock-93CH-4965805
aTyr Pharma announced it filed a prospectus supplement to sell up to $79.99 million in common stock, a substantial amount compared to its current $15.4 million market capitalization. This move follows an 80% year-to-date stock decline and recent news of a Phase 3 trial initiation, a lowered price target by Piper Sandler, and a 1-for-40 reverse stock split. The shares will be sold through an existing Open Market Sale Agreement with Jefferies LLC.
Advertisement

aTyr Pharma files to offer up to $80M in common stock via ATM program

https://www.streetinsider.com/Corporate+News/aTyr+Pharma+files+to+offer+up+to+%2480M+in+common+stock+via+ATM+program/27307873.html
aTyr Pharma, Inc. has filed a prospectus supplement to offer and sell up to $79,994,251 in common stock through an At-The-Market (ATM) program. This offering will utilize an existing agreement with Jefferies LLC, allowing for sales at prevailing market prices. The move is made under a shelf registration statement declared effective in August 2025.

aTyr Pharma files prospectus to sell up to $79.99 million in common stock

https://www.investing.com/news/sec-filings/atyr-pharma-files-prospectus-to-sell-up-to-7999-million-in-common-stock-93CH-5009180
aTyr Pharma (NASDAQ:ATYR) has filed a prospectus to sell up to $79.99 million in common stock, a substantial amount compared to its current $15.4 million market capitalization. This move comes after the stock experienced an 80% year-to-date decline to $6.35 per share. The company recently announced Q3 2026 earnings, initiated a Phase 3 trial for efzofitimod, and plans a 1-for-40 reverse stock split.

aTyr Pharma files prospectus to sell up to $79.99 million in common stock By Investing.com

https://za.investing.com/news/stock-market-news/atyr-pharma-files-prospectus-to-sell-up-to-7999-million-in-common-stock-93CH-4559172
aTyr Pharma (NASDAQ:ATYR) has filed a prospectus to sell up to $79.99 million in common stock, a substantial amount compared to its current market capitalization of $15.4 million, following an 80% year-to-date stock decline. The company also recently announced its Q3 2026 earnings, initiated a Phase 3 trial for efzofitimod, and plans a 1-for-40 reverse stock split. Piper Sandler adjusted its price target for aTyr Pharma from $280 to $35 while maintaining an Overweight rating.

Piper Sandler lowers aTyr Pharma stock price target on valuation By Investing.com

https://uk.investing.com/news/stock-market-news/piper-sandler-lowers-atyr-pharma-stock-price-target-on-valuation-93CH-4963312
Piper Sandler has lowered its price target for aTyr Pharma (NASDAQ:ATYR) shares from $280 to $35, while maintaining an Overweight rating. This adjustment follows the company's third-quarter 2026 earnings report and a recent 1-for-40 reverse stock split. The biotech firm is initiating Phase 3 trials for efzofitimod in pulmonary sarcoidosis patients and ended Q3 2026 with $50.3 million in cash.

FDA and aTyr align on a lung disease trial plan. aTyr is prioritizing partners to advance it.

https://www.stocktitan.net/news/ATYR/a-tyr-pharma-announces-third-quarter-2026-results-and-provides-jcnda9dt47od.html
aTyr Pharma (Nasdaq: ATYR) announced alignment with the FDA on the protocol for a Phase 3 study of efzofitimod in pulmonary sarcoidosis patients with restrictive lung disease, targeting forced vital capacity as the primary endpoint. While initial study activities have begun, further advancement depends on securing strategic partnerships or licensing arrangements. The company also reported a narrowed net loss of $18.261 million for Q3 2026 and expects current operations to be funded into late 2028.
Advertisement

aTyr Pharma, Inc. (ATYR) Misses Q3 EPS by 733c

https://www.streetinsider.com/Earnings/aTyr+Pharma%2C+Inc.+%28ATYR%29+Misses+Q3+EPS+by+733c/27299967.html
aTyr Pharma, Inc. (NASDAQ: ATYR) reported a significant miss in its Q3 EPS, with ($7.43) per share, which is $7.33 worse than the analyst estimate of ($0.10). The article provides the reported EPS figure and links for further earnings history and related data for the company.

aTyr Pharma Announces Third Quarter 2026 Results and Provides Corporate Update

https://www.manilatimes.net/2026/11/06/tmt-newswire/globenewswire/atyr-pharma-announces-third-quarter-2026-results-and-provides-corporate-update/2463475
aTyr Pharma announced its Q3 2026 results and a corporate update, highlighting alignment with the FDA for a Phase 3 study of efzofitimod in pulmonary sarcoidosis. The company plans to prioritize strategic partnerships to advance this study and reported $50.3 million in cash, projecting a cash runway into late 2028. Additionally, aTyr completed enrollment for its Phase 2 EFZO-CONNECT™ study and published results from its Phase 3 EFZO-FIT™ study.

aTyr Pharma Announces Third Quarter 2026 Results and Provides Corporate Update

https://www.globenewswire.com/news-release/2026/11/05/3397007/0/en/atyr-pharma-announces-third-quarter-2026-results-and-provides-corporate-update.html
aTyr Pharma reported its third-quarter 2026 financial results and provided a corporate update, highlighting alignment with the FDA for a proposed Phase 3 study of efzofitimod in pulmonary sarcoidosis. The company plans to prioritize strategic partnerships to advance this study. aTyr Pharma ended the quarter with $50.3 million in cash, providing a cash runway into late 2028 based on current operational plans.

Five reporting persons each report a 0% stake in aTYR Pharma (ATYR).

https://www.stocktitan.net/sec-filings/ATYR/schedule-13g-a-a-tyr-pharma-inc-amended-passive-investment-disclosure-b39f12f8a468.html
Five reporting persons, including Federated Hermes, Inc., Voting Shares Irrevocable Trust, Thomas R. Donahue, Ann C. Donahue, and J. Christopher Donahue, have each reported a 0% beneficial ownership stake in aTYR Pharma (ATYR). This information comes from a Schedule 13G/A amendment filed with the SEC on November 4, 2026, indicating zero beneficially owned shares and no voting or dispositive power. The filing signifies a neutral impact and sentiment regarding the company's control.

aTyr Pharma Inc (471A.HA) stock historical prices and data

https://uk.finance.yahoo.com/quote/471A.HA/history/
This article provides historical price data for aTyr Pharma Inc (471A.HA) stock, listed on the Hanover exchange and priced in EUR. It presents daily open, high, low, close, and adjusted close prices, along with volume, for a period leading up to October 30, 2026. The data shows significant fluctuations in the stock's value over the displayed dates.
Advertisement

aTyr Pharma Inc (471A.HA) interactive stock chart

https://uk.finance.yahoo.com/quote/471A.HA/chart/
This page provides an interactive stock chart for aTyr Pharma Inc (471A.HA) on Yahoo Finance, showing its current stock price, recent performance, and historical data. It also lists recent news, including publications of study results for Efzofitimod, a reverse stock split, and research collaborations. The stock showed a significant decrease at close.

aTyr Pharma Inc (471A.HA) latest stock news and headlines

https://uk.finance.yahoo.com/quote/471A.HA/news/
This article provides recent news and performance data for aTyr Pharma Inc (471A.HA). Key updates include the publication of Phase 3 study results for Efzofitimod, a one-for-40 reverse stock split, and a new research collaboration. The company's stock has seen significant negative returns year-to-date and over the past one and three years, sharply underperforming the S&P 500.

aTyr Pharma, Inc. (ATYR) Seasonal Returns Chart - Yahoo Finance

https://ca.finance.yahoo.com/quote/ATYR/seasonality/
The Yahoo Finance page for aTyr Pharma, Inc. (ATYR) displays an error, stating "Oops, something went wrong." Despite the error, some information is visible, including the stock's current price of 4.9400, a decrease of 8.01%, as of the market close on October 30. The page also shows a "Historical Seasonality Average monthly price return, 2016 - 2026" chart, though the chart content itself is not loaded due to the error.

Quick ratio of aTyr Pharma, Inc. – FWB:471

https://www.tradingview.com/symbols/FWB-471/financials-statistics-and-ratios/quick-ratio/
This article presents the quick ratio for aTyr Pharma, Inc. (FWB:471) on the Frankfurt Stock Exchange. It notes that the market was closed with no trades. The content is primarily a data point rather than an analytical piece.

Operating expenses (excl. COGS) of aTyr Pharma, Inc. – FWB:471

https://www.tradingview.com/symbols/FWB-471/financials-income-statement/operating-expenses/
This article provides financial information for aTyr Pharma, Inc. (FWB:471) focusing specifically on its operating expenses, excluding the cost of goods sold. The content is presented within the TradingView platform, indicating it's a snippet of financial data accessible to users.
Advertisement

aTyr Pharma (NASDAQ:ATYR): Efzofitimod Phase 3 Data Published in The Lancet, Supports Continued Development in Lung Disease

https://kalkine.com.au/stock-analysis/healthcare/atyr-pharma-nasdaqatyr-efzofitimod-phase-3-data-published-in-the-lancet-supports-continued-development-in-lung-disease
aTyr Pharma announced the publication of Phase 3 clinical results for its lead drug candidate, efzofitimod, in The Lancet Respiratory Medicine. While the EFZO-FIT study did not meet its primary endpoint of steroid dose reduction, the 5.0 mg/kg dose demonstrated clinical benefit in multiple patient-reported outcome measures and maintained lung function. The company is advancing a new global Phase 3 study for efzofitimod in pulmonary sarcoidosis and a Phase 2 study in systemic sclerosis-related interstitial lung disease.

aTyr Pharma (NASDAQ:ATYR): Efzofitimod Phase 3 Data Published in The Lancet, Supports Continued Development in Lung Disease

https://kalkine.com.au/news/healthcare/atyr-pharma-nasdaqatyr-efzofitimod-phase-3-data-published-in-the-lancet-supports-continued-development-in-lung-disease
aTyr Pharma (NASDAQ:ATYR) announced the publication of Phase 3 clinical results for its lead drug candidate, efzofitimod, in The Lancet Respiratory Medicine. While the EFZO-FIT study did not meet its primary endpoint of significant steroid dose reduction, the 5.0 mg/kg dose demonstrated clinical benefit in patient-reported outcomes and preserved lung function in pulmonary sarcoidosis patients. The company is continuing development with new Phase 3 and Phase 2 studies, emphasizing efzofitimod's novel immunological approach.

aTyr Pharma Announces Publication of Results from the Phase 3 EFZO-FIT™ Study of Efzofitimod in Pulmonary Sarcoidosis in The Lancet Respiratory Medicine

https://finance.yahoo.com/healthcare/articles/atyr-pharma-announces-publication-results-120000481.html
aTyr Pharma announced the publication of Phase 3 EFZO-FIT™ study results for efzofitimod in pulmonary sarcoidosis in The Lancet Respiratory Medicine. The study showed that while efzofitimod did not achieve a statistically significant steroid reduction, it improved multiple patient-reported outcomes and maintained lung function, reinforcing its potential for advancing pulmonary sarcoidosis care. These findings are considered a significant advancement in understanding patient management and evaluating new therapies for this condition.

aTyr Pharma Announces Publication of Results from the Phase 3 EFZO-FIT™ Study of Efzofitimod in Pulmonary Sarcoidosis in The Lancet Respiratory Medicine

https://www.globenewswire.com/news-release/2026/10/29/3391199/0/en/atyr-pharma-announces-publication-of-results-from-the-phase-3-efzo-fit-study-of-efzofitimod-in-pulmonary-sarcoidosis-in-the-lancet-respiratory-medicine.html
aTyr Pharma has announced the publication of results from its Phase 3 EFZO-FIT™ study of efzofitimod for pulmonary sarcoidosis in The Lancet Respiratory Medicine. The study, involving 268 patients, showed that while efzofitimod did not achieve a statistically significant steroid reduction compared to placebo, it significantly improved multiple patient-reported outcomes and was generally well-tolerated. These findings reinforce the potential of efzofitimod to advance care for pulmonary sarcoidosis patients by enabling steroid reduction and enhancing quality of life.

An experimental lung treatment missed its main goal. Its higher dose improved health scores versus a dummy treatment.

https://www.stocktitan.net/news/ATYR/a-tyr-pharma-announces-publication-of-results-from-the-phase-3-efzo-mluockvzzx02.html
aTyr Pharma announced the publication of Phase 3 EFZO-FIT study results for efzofitimod in pulmonary sarcoidosis in The Lancet Respiratory Medicine. While the trial did not meet its primary endpoint of significant steroid reduction, the 5.0 mg/kg dose demonstrated benefits across several patient-reported outcomes, including lung symptoms, fatigue, and general health, with a favorable safety profile. The company is initiating activities for another global Phase 3 trial.
Advertisement

aTyr Pharma Inc (471A.HM) Seasonal returns chart

https://au.finance.yahoo.com/quote/471A.HM/seasonality/
The article displays a seasonal returns chart for aTyr Pharma Inc (471A.HM), showing the average monthly price return from 2025 to 2026. The stock was trading at 0.0576 EUR, down 31.91% at the close on October 28.

aTyr Pharma Inc (471A.HA) valuation measures and financial statistics

https://uk.finance.yahoo.com/quote/471A.HA/key-statistics/
This article provides detailed valuation measures and financial statistics for aTyr Pharma Inc (471A.HA). It includes data on market capitalization, price/sales, price/book ratios, and various profitability, management effectiveness, and income statement figures. The report also covers balance sheet details, cash flow, trading information, share statistics, and dividend data, highlighting the company's financial health and stock performance metrics.

aTyr Pharma Inc (471A.HA) insider ownership and holdings – Yahoo Finance

https://sg.finance.yahoo.com/quote/471A.HA/insider-roster/
This Yahoo Finance page provides information on aTyr Pharma Inc (471A.HA), including its insider ownership and holdings. The stock experienced a significant drop of 31.91% to 0.0576 EUR and announced a 1-for-40 reverse stock split effective October 29, 2026.

aTyr Pharma Inc (471A.HA) stock price, news, quote and history

https://sg.finance.yahoo.com/quote/471A.HA/
This Yahoo Finance page provides a summary of aTyr Pharma Inc (471A.HA) stock information. It shows the current stock price, which is 0.0576 EUR, down 31.91%, as of October 28th at 8:19:36 am GMT+1. The page also includes historical data, key statistics, and valuation measures, though many specific financial figures are listed as unavailable.

aTyr Pharma to implement 1-for-40 reverse stock split

https://www.investing.com/news/company-news/atyr-pharma-to-implement-1for40-reverse-stock-split-93CH-4975686
aTyr Pharma, Inc. (NASDAQ: ATYR) announced a 1-for-40 reverse stock split of its common stock, effective at 5:00 p.m. ET on Wednesday, October 28, 2026. This action, approved by stockholders, is intended to meet the Nasdaq Capital Market's minimum bid price requirement. The split will reduce outstanding shares from approximately 100.5 million to 2.5 million, with no fractional shares issued.
Advertisement

aTyr Pharma implements one-for-forty split. aTyr Pharma stock is valued at USD 11.3 million

https://www.ad-hoc-news.de/boerse/news/corporate-news/atyr-pharma-implements-one-for-forty-split-atyr-pharma-stock-is-valued-at-usd-11-3-million/70422706
aTyr Pharma has filed for a one-for-forty reverse stock split, effective October 28, 2026, which will reduce the number of common shares from 100.5 million to 2.5 million. The company's stock currently trades at EUR 0.10, with a Nasdaq market capitalization of USD 11.3 million. Additionally, aTyr Pharma expanded its ATYR2810 research into pediatric osteosarcoma through a collaboration with Albert Einstein College of Medicine and Montefiore Einstein.

Form 8K aTyr Pharma Inc For: 27 October By Investing.com

https://ng.investing.com/news/stock-market-news/form-8k-atyr-pharma-inc-for-27-october-93CH-2760214
This article announces that aTyr Pharma Inc. filed a Form 8K on October 27, 2026. The filing is a standard disclosure document for significant events that shareholders should know about. The company's stock symbol is ATYR.

aTyr Pharma announces 1-for-40 reverse stock split effective October 28

https://www.investing.com/news/sec-filings/atyr-pharma-announces-1for40-reverse-stock-split-effective-october-28-93CH-4975737
aTyr Pharma (NASDAQ:ATYR) will execute a 1-for-40 reverse stock split of its common stock, effective October 28 at 5:00 p.m. Eastern Time. This move, approved by stockholders and the board, aims to address shares trading near their 52-week low. Following the split, the number of outstanding shares will decrease significantly, and the stock will begin trading on a split-adjusted basis on the Nasdaq Capital Market.

aTyr Pharma Sets 1-for-40 Reverse Stock Split | ATYR Stock News

https://www.stocktitan.net/news/ATYR/a-tyr-pharma-announces-one-for-40-reverse-stock-v6ep9bcnq2fp.html
aTyr Pharma will implement a 1-for-40 reverse stock split, effective October 28, 2026, to regain compliance with Nasdaq's minimum bid price requirement. This action will reduce the number of outstanding shares from approximately 100.5 million to 2.5 million, with split-adjusted trading beginning October 29, 2026. Stockholders approved the split on October 16, 2026.

aTyr Pharma Announces One-for-40 Reverse Stock Split

https://finance.yahoo.com/markets/stocks/articles/atyr-pharma-announces-one-40-130000059.html
aTyr Pharma, Inc. announced a 1-for-40 reverse stock split of its common stock, effective October 28, 2026, with post-split trading beginning October 29, 2026. This action is intended to help the company comply with Nasdaq's minimum bid price requirement. The reverse split will reduce the number of outstanding shares from approximately 100.5 million to 2.5 million.
Advertisement

aTyr Pharma Announces One-for-40 Reverse Stock Split

https://www.globenewswire.com/news-release/2026/10/27/3389032/0/en/atyr-pharma-announces-one-for-40-reverse-stock-split.html
aTyr Pharma, Inc. (Nasdaq: ATYR) announced a 1-for-40 reverse stock split, effective October 28, 2026, to comply with Nasdaq's minimum bid price requirement. The company's common stock will trade on a split-adjusted basis starting October 29, 2026, reducing outstanding shares from approximately 100.5 million to 2.5 million. Fractional shares will be rounded up, and the split proportionally adjusts outstanding equity awards.

aTyr Pharma, Inc. Estimates – NASDAQ:ATYR

https://www.tradingview.com/symbols/NASDAQ-ATYR/financials-estimates/
This article provides financial estimates and actuals for aTyr Pharma, Inc. (NASDAQ: ATYR) through TradingView. It allows users to explore reported financial data and analyst estimates across various financial statements and visualize trends over time. The platform also offers comparison tools for actual results against average, high, and low estimates.

aTyr Pharma, Inc. Estimates – LS:A2PM86

https://www.tradingview.com/symbols/LS-A2PM86/financials-estimates/
The article provides an overview of aTyr Pharma, Inc. (A2PM86) financials and estimates on TradingView. It directs users to explore reported financial data and analyst estimates across various statements, allowing comparison of actual results with average, high, and low estimates, and visualization of trends. The platform includes income statement, balance sheet, cash flow, and valuation metrics for both annual and quarterly data.

aTyr Pharma, Inc. Stock 12‑Month Price Target Raised to $3.2, Implies 1757% Upside

https://www.tradingview.com/news/tradingview:6dfef5ac8c636:0-atyr-pharma-inc-stock-12-month-price-target-raised-to-3-2-implies-1757-upside/
aTyr Pharma, Inc. (ATYR) has seen its average 12-month price target increase from $2.83 to $3.2, implying a significant 1757% potential upside based on its Oct. 21 closing price. This revised target comes from estimates by 5 analysts, with individual forecasts ranging from $1 to $7 per share. The consensus rating for the stock remains a "Buy" from 7 covering analysts, consisting of 3 Buys and 4 Holds.

aTyr Pharma stock gains 185.71 percent versus Frankfurt close

https://www.ad-hoc-news.de/boerse/news/nebenwerte/atyr-pharma-stock-gains-185-71-percent-versus-frankfurt-close/70376699
aTyr Pharma's stock surged 185.71 percent against its Frankfurt close on October 20, 2026, reaching EUR 0.16 at Lang & Schwarz. This significant jump is attributed to a low Frankfurt comparison base, rather than a new fundamental valuation. The clinical-stage biotechnology company, which reported a Q2 2026 net loss of USD 10.31 million, is focused on its lead candidate efzofitimod and anticipates reporting third-quarter results on November 5, 2026.
Advertisement

About 1,000 U.S. children and teens are diagnosed yearly with a common bone cancer. aTyr will study an antibody.

https://www.stocktitan.net/news/ATYR/a-tyr-pharma-announces-research-collaboration-with-montefiore-yp5n82vfbgs8.html
aTyr Pharma announced a research collaboration with Albert Einstein College of Medicine to study ATYR2810, a monoclonal antibody targeting the neuropilin-2 (NRP2) receptor, in pediatric osteosarcoma. This collaboration aims to advance the development and testing of ATYR2810, which has shown anti-tumor effects in other preclinical cancer models, potentially offering a new approach to combat aggressive bone cancer in children and adolescents. The research will be led by Dr. Bang H. Hoang and will explore how blocking NRP2 signaling could disrupt immunosuppression in tumors.

aTyr Pharma partners with Montefiore Einstein on bone cancer research

https://www.streetinsider.com/Corporate+News/aTyr+Pharma+partners+with+Montefiore+Einstein+on+bone+cancer+research/27200534.html
aTyr Pharma has announced a research collaboration with Albert Einstein College of Medicine to study ATYR2810, its monoclonal antibody, in pediatric bone cancers. The research will focus on ATYR2810's ability to disrupt myeloid-driven immune suppression by targeting the neuropilin-2 (NRP2) receptor, aiming to address the therapeutic challenges of aggressive solid tumors like osteosarcoma. This partnership will investigate NRP2's role in osteosarcoma, a common and aggressive bone cancer in children.

aTyr Pharma Announces Research Collaboration with Montefiore Einstein

https://www.globenewswire.com/news-release/2026/10/19/3383277/0/en/atyr-pharma-announces-research-collaboration-with-montefiore-einstein.html
aTyr Pharma has announced a research collaboration with Albert Einstein College of Medicine to advance the development of ATYR2810, the company's anti-NRP2 antibody, for preclinical studies in pediatric osteosarcoma. Led by Dr. Bang H. Hoang, the research will investigate ATYR2810's ability to disrupt myeloid-driven immune suppression by blocking the NRP2 signaling pathway, offering a potential new approach to treating this aggressive pediatric bone cancer. This collaboration aims to understand NRP2's role in osteosarcoma, a disease with significant unmet needs, especially in managing recurrence.

aTyr Pharma stock fell 5.56 percent to USD 0.17 on October 16, 2026

https://www.ad-hoc-news.de/boerse/news/nebenwerte/atyr-pharma-stock-fell-5-56-percent-to-usd-0-17-on-october-16-2026/70349770
aTyr Pharma's stock dropped by 5.56 percent to USD 0.17 on October 16, 2026, closing at the lower end of its 52-week range. The company's market capitalization stood at USD 17.1 million, and its trailing P/E ratio was minus 0.28. aTyr Pharma is focused on developing therapies for fibrosis and inflammation, with its lead candidate efzofitimod.

aTyr Pharma stock heads into November 5 earnings at USD 18.9 million value

https://www.ad-hoc-news.de/boerse/news/nebenwerte/atyr-pharma-stock-heads-into-november-5-earnings-at-usd-18-9-million-value/70332417
aTyr Pharma (ATYR) is preparing to report its earnings on November 5, 2026. The biotechnology company reported second-quarter earnings per share of USD -0.11 and currently holds a market capitalization of USD 18.9 million. The stock was trading at EUR 0.17 on Lang & Schwarz and USD 0.19 on Nasdaq, with a 52-week range of USD 0.18 to USD 1.11.
Advertisement
Advertisement
Advertisement
Advertisement

Sign Up free to view live trades and discussion forum to make more informed financial decisions. No credit card is required for sign up!
View Daily Trades
Join Discussion

Advertisement
Advertisement
Advertisement
Advertisement